US-based pharmaceutical company Nuvo has announced its intention to conduct a Phase III trial of Pennsaid 2% in Germany to treat acute ankle sprains.

Pennsaid 2% is a topical, non-steroidal, anti-inflammatory drug (NSAID) composed of 2% diclofenac sodium.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It is a gel formulation applied in a metered dose pump bottle.

The trial is designed to support regulatory approvals in the European Union, Canada and Australia.

"The trial incorporates what we learned from a similar trial conducted in 2015 that produced encouraging results, and we believe Pennsaid 2% can show positive results in this setting."

Nuvo president and CEO John London said: "The trial incorporates what we learned from a similar trial conducted in 2015 that produced encouraging results, and we believe Pennsaid 2% can show positive results in this setting.

See Also:

"In particular, we have changed the primary endpoint (pain on movement) to the third day after initial treatment, which was a secondary endpoint whereby Pennsaid 2% demonstrated statistical significance in the 2015 trial."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The placebo-controlled, multi-centre trial plans to involve approximately 130 patients who are experiencing a grade I or grade II ankle sprain.

During the trial, the patients will be randomly assigned on a double-blind basis to an active arm or a placebo arm and will be administered to either Pennsaid 2% or a placebo, which consists of all the constituents of Pennsaid 2% except its active ingredient diclofenac sodium.

It will be applied on the patients' injured ankles twice a day for a duration of eight days.

The trial is primarily focused on achieving a reduction in pain of movement (POM) after three days, while the secondary endpoints are to reduce tenderness, ankle function, ankle swelling and achieve an overall clinical benefit of the medication.